ARTICLE | Finance
ImCheck raises over $100M to progress gamma delta T cell mAb
Andera, Earlybird-led series C should reach Phase II data for ICT01, plus progress butyrophilin-targeted pipeline
June 14, 2022 12:42 AM UTC
ImCheck has raised more than $100 million to obtain clinical proof-of-concept for its γδ T cell activating mAb and progress a pipeline of immunology programs.
ImCheck Therapeutics S.A.S. raised €96 million ($100.5 million) in a series C round co-led by new investors Andera Partners and Earlybird, making it the second-largest private financing round for a European biotech this year...